BOSTON, Dec. 30, 2011 (GLOBE NEWSWIRE) -- FluoroPharma Medical (OTCBB:FPMI) is pleased to announce that Lawrence Atinsky has been appointed to the Board of Directors of FluoroPharma effective January 3rd, 2012. Mr. Atinsky is currently a partner at Ascent Biomedical Ventures (ABV), a leading venture capital firm that focuses on investing in seed and early-stage biomedical technology companies developing medical devices, biopharmaceuticals, healthcare services, and information technology. Over the past ten years, Mr. Atinsky has worked closely with the management teams of a wide range of biotechnology companies helping them execute strategic growth plans. Prior to joining ABV, Mr. Atinsky was an attorney at Skadden Arps where he specialized in mergers and acquisitions. “I am delighted to welcome Lawrence to the FluoroPharma Board. His legal background, along with his extensive biotech business experience, brings invaluable knowledge and will complement the considerable expertise of the Board,” commented Thijs Spoor, FluoroPharma’s President, and Chief Executive Officer.
